Discovery and characterization of potent small molecule inhibitors of the high affinity proline transporter.
The mammalian proline transporter (PROT) is a high affinity Na(+)/Cl(-)-dependent transporter expressed in specific regions of the brain. It is homologous to other neurotransmitter transporters such as glycine, norepinephrine, serotonin, and dopamine transporters. PROT is enriched in glutamatergic synaptic terminals and may play an important role in the regulation of excitatory neurotransmission. No non-peptide small molecule inhibitors have been described for this transporter. To study its physiological role in the central nervous system and evaluate its potential as a therapeutic target, we established cell lines that stably express recombinant hPROT and characterized its kinetic properties for proline uptake. We then screened for inhibitors and identified a series of compounds that inhibit hPROT-mediated proline uptake. A known compound, benztropine, was found to inhibit hPROT with an IC(50) of 0.75microM. A series of novel compounds were also found, one of which, LP-403812, showed an IC(50) of approximately 0.1microM on both recombinant human and mouse PROT without significant inhibition of glycine and dopamine transporters at concentrations up to 10microM. This compound also inhibited proline transporter activity of mouse brain synaptosomes with the same potency. These inhibitors provide important tools for the understanding of PROT functions in the brain and may lead to the development of therapeutic agents for certain neurological disorders.
Yu
Xuan-Chuan
XC
Department of Pharmaceutical Discovery, Lexicon Pharmaceuticals Inc., The Woodlands, TX 77381, USA. syu@lexpharma.com
Zhang
Wandong
W
Oldham
Arian
A
Buxton
Eric
E
Patel
Shiv
S
Nghi
Nguyen
N
Tran
David
D
Lanthorn
Thomas H
TH
Bomont
Catherine
C
Shi
Zhi-Cai
ZC
Liu
Qingyun
Q
D026921:Amino Acid Transport Systems, Neutral / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001483:Base Sequence; D001590:Benztropine / Q000737:chemistry / Q000494:pharmacology; D001921:Brain / Q000378:metabolism* / Q000648:ultrastructure; D019556:COS Cells; D002460:Cell Line; D002522:Chlorocebus aethiops; D003001:Cloning, Molecular; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004791:Enzyme Inhibitors / Q000302:isolation & purification / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D015394:Molecular Structure; D018727:Muscarinic Antagonists / Q000494:pharmacology; D017729:Presynaptic Terminals / Q000378:metabolism* / Q000648:ultrastructure; D011720:Pyrazoles / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects* / Q000502:physiology; D013574:Synaptosomes; D013844:Thiazoles / Q000494:pharmacology*; D014162:Transfection
D026921:Amino Acid Transport Systems, Neutral; D004791:Enzyme Inhibitors; C540683:LP 403812; D018727:Muscarinic Antagonists; D011720:Pyrazoles; D011994:Recombinant Proteins; D013844:Thiazoles; C041832:proline transport protein; D001590:Benztropine